Global sarcopenia treatment market to hit $4.97 billion by 2030 at 6% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Sarcopenia Treatment Market During 2026–2030?

The sarcopenia treatment market has experienced strong growth in recent years. It is projected to expand from $3.72 billion in 2025 to $3.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The growth observed in the past can be attributed to factors such as an expanding elderly population base, increasing awareness of age-related muscle loss, reliance on physical therapy and nutritional support, the limited availability of approved drug therapies, and a rising incidence of mobility-related disorders.

The sarcopenia treatment market is projected for significant expansion in the coming years, anticipated to reach $4.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This growth during the forecast period is attributable to several factors, including the emergence of innovative pharmacological therapies, a heightened emphasis on prompt diagnosis and intervention, increasing healthcare expenditure dedicated to geriatric care, the escalating incidence of chronic illnesses impacting muscle health, and the expansion of clinical trials aimed at muscle regeneration. Key trends expected within the forecast period encompass a greater utilization of integrated pharmacological and exercise-based approaches, the increasing incorporation of nutritional supplements in managing sarcopenia, an uptick in clinical investigations into myostatin inhibitors and anabolic agents, enhanced identification of sarcopenia among older adults, and a broader integration of physical therapy into treatment protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

What Major Factors Are Driving The Sarcopenia Treatment Market Forward?

The sarcopenia treatment market is anticipated to grow as a result of increasing malnutrition. Malnutrition refers to deficiencies, excesses, or imbalances in an individual’s consumption of energy and nutrients, encompassing both undernutrition and conditions such as overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment addresses the simultaneous presence of malnutrition and sarcopenia in older adults via interventions like nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For instance, in January 2025, according to a report published by the United States Department of Agriculture, a US-based government department, household food insecurity affected 17.9% of families with children in 2023, impacting roughly 6.5 million such households. Consequently, the rise in malnutrition is propelling the expansion of the sarcopenia treatment market.

What Are The Main Segments Within The Sarcopenia Treatment Market Segment Structure?

The sarcopenia treatment market covered in this report is segmented –

1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types

2) By Type: Primary Sarcopenia, Secondary Sarcopenia

3) By Route Of Administration: Oral, Parenteral, Enteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein

2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin

3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate

4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions

Which Trends Are Impacting The Progress Of The Sarcopenia Treatment Market?

Companies operating within the sarcopenia treatment market are increasingly directing their efforts towards developing numerous advanced clinical study options to ensure superior treatment choices. A clinical study represents a systematic investigation conducted on human participants to assess the safety, effectiveness, or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced that the Food and Drug Administration (FDA) authorized the initiation of the SARA-31 Phase 3 study for sarcopenia. This study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients who are at risk of motor disability. This particular study signifies a substantial advance in technological and pharmaceutical treatment approaches, potentially offering benefits in both efficacy and safety for individuals with severe sarcopenia. It holds the distinction of being the first-ever Phase 3 study in sarcopenia and has received FDA authorization. The study is planned to include approximately 900 patients over 65 years old who have sarcopenia, low walking speed, and low hand grip strength. The primary endpoint will be the evaluation of the risk of major mobility disability (MMD), along with walking speed, hand grip strength, and patient-reported quality of life.

Who Are The Companies Participating In The Sarcopenia Treatment Market?

Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill

Get The Full Sarcopenia Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Which Region Is The Leading Market For The Sarcopenia Treatment Market?

North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Sarcopenia Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Browse Through More Reports Similar to the Global Sarcopenia Treatment Market 2026, By The Business Research Company

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Market Report

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Vulvodynia Treatment Market Report

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795